VACH

Voyager Acquisition Corp./Cayman Islands

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. E9 · CIK 0002006815
$9.60 -8.75%
Vol
Press Releases2

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
$0.00 $0.00 $0.00 $0.0B
Next Q
$0.00 $0.00 $0.00 $0.0B
Current FY
$0.00 $0.00 $0.00 $0.0B
Next FY
$0.00 $0.00 $0.00 $0.0B

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 13, 2026
earnings_calendar
VACH Q1 2026 Earnings Scheduled — 2026-05-13
Mar 30, 2026
earnings_calendar
VACH Q4 2025 Earnings Scheduled — 2026-03-30
Mar 13, 2026
m_and_a
Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG
<p align="justify">BROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager”
Mar 11, 2026
m_and_a
Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG
<p align="justify">BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager”